Resource Library

Whether you have experienced a medication error in your organization or you are proactively implementing prevention strategies, you are not alone. Thousands of organizations worldwide have relied on ISMP's resources for institutional change to reduce errors on a daily basis. These resources are developed from ISMP's review of reports through its national error reporting programs, peer-reviewed articles in its publications, and/or consensus gathering summits on topics pertinent to specific errors  or hazards. ISMP offers a wide range of downloadable and easy to use resources. Many are free.

All Resources

Filter by type
Since 1994, when ISMP first became the nation’s only nonprofit organization devoted entirely to preventing medication errors, we have served as a vital force for progress in medication safety through our unyielding advocacy and the development of resources and learning opportunities for healthcare...
Since January 2019, ISMP has learned about 4 children who received vin CRIS tine erroneously by the intrathecal route of administration, each suffering a very painful death. Three of the children were from Guyana, and one was from Norway. The child from Norway had a brain tumor and was just 6 years...
Most people are aware of the need to keep medications out of children’s reach, but they don’t necessarily realize that similar rules apply when it comes to keeping pets safe. Pets can also get into medications that are not intended for them, which could cause harm. One case in point was recently...
Medication-related warning systems are often used to inform both practitioners and consumers about new risks, or remind them about known risks associated with the use of medications. The warning system may ask the recipient to choose between two or more courses of action, present only one safe...
In academic teaching hospitals, medical residents typically enter most of the medication orders for patients using electronic prescribing (e-prescribing) systems. However, little is known about the association between the residents’ level of training and the frequency of medication prescribing...
The US Food and Drug Administration (FDA) approved LUMOXITI (moxetumomab pasudotox-tdfk) injection in September 2018. Lumoxiti is a CD22-directed cytotoxin indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia who received at least two prior systemic therapies...